Investigational drug · Phase 2
BX004
Also called: Combination of nebulized bacteriophages targeting Pseudomonas aeruginosa
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF).
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 22, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "BX004"
First trial start
2025
Jul 2, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BX004", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Pseudomonas Aeruginosa Infection
- Cystic Fibrosis (CF)
Approved drugs for the same conditions: Cystic fibrosis · Infectious disease and vaccines · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "BX004" as an intervention, largest first.
BiomX LtdIndustry
NCT06998043 · 63 participants (planned) · Start Jul 2, 2025 · Primary completion Mar 2026
Drug: BX004 · For: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis (CF)
Sites: Birmingham, Alabama; Anchorage, Alaska; Little Rock, Arkansas · 14 sites in all
BiomX, Inc.Industry
NCT05010577 · 43 participants · Start Jun 21, 2022 · Primary completion Mar 10, 2024
Drug: BX004-A; Placebo · For: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis
Sites: Birmingham, Alabama; Anchorage, Alaska; Little Rock, Arkansas · 28 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Author Correction: Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial.
Weiner I, Kahan-Hanum M, Buchstab N, et al. · Nat Commun 2026
- Antibiotics and non-traditional antimicrobial agents for Pseudomonas aeruginosa in clinical phases 1, 2, and 3 trials.
Romanos LT, Kontogiannis DS, Tsiampali C, et al. · Expert Opin Investig Drugs 2025
- Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial.
Weiner I, Kahan-Hanum M, Buchstab N, et al. · Nat Commun 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.